Currently, the main nine driver mutations targeted in advanced NSCLC are the following: epidermal growth factor receptor (EGFR)‐mutations, anaplastic lymphoma kinase (ALK)‐fusions, ROS1 proto‐oncogene (ROS1)‐fusions, KRAS mutations, BRAF V600E mutation, mesenchymal‐epithelial transition (MET) exon 14 skipping, RET fusions, human epidermal growth factor receptor 2 (HER2) mutations, and neurotrophic tyrosine receptor kinase (NTRK) fusions. Here, ERBB2 is linked to non-small cell lung carcinoma.